AxoGen (NASDAQ:AXGN) Director John Johnson Sells 11,050 Shares

AxoGen, Inc. (NASDAQ:AXGN) Director John Johnson sold 11,050 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the sale, the director owned 11,050 shares in the company, valued at approximately $478,023. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AxoGen Trading Down 3.1%

Shares of AxoGen stock opened at $42.06 on Friday. AxoGen, Inc. has a 12-month low of $9.22 and a 12-month high of $45.83. The stock has a market cap of $2.24 billion, a P/E ratio of -65.72 and a beta of 1.17. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average is $34.20 and its 200-day moving average is $31.15.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The company had revenue of $61.46 million for the quarter, compared to the consensus estimate of $57.85 million. Equities research analysts predict that AxoGen, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AxoGen

A number of large investors have recently added to or reduced their stakes in AXGN. MCF Advisors LLC bought a new stake in AxoGen in the 4th quarter valued at $30,000. Aquatic Capital Management LLC raised its stake in AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 1,269 shares during the period. Arax Advisory Partners raised its stake in AxoGen by 362.4% in the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 819 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in AxoGen in the 4th quarter valued at $36,000. Finally, Kestra Advisory Services LLC acquired a new position in AxoGen in the 4th quarter valued at $39,000. Institutional investors own 80.29% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Citigroup reiterated an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Canaccord Genuity Group upped their price objective on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Zacks Research cut AxoGen from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Wells Fargo & Company increased their price target on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Finally, Lake Street Capital increased their price target on AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $46.50.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.